Incretin biology and GIP co-agonism: a research overview
A neutral overview of the incretin system and how single, dual and triple receptor agonism are studied in metabolic-signaling research. Educational only.
A neutral overview of incretin biology and receptor co-agonism as described in the research literature. This page is educational and describes mechanisms only — for the dedicated GLP-1 overview, see the GLP-1 pathway research overview.
The incretin system
The incretin effect is the augmented insulin response to oral versus intravenous glucose observed in research models. Its two principal peptides are GLP-1 and GIP (glucose-dependent insulinotropic polypeptide), released from intestinal enteroendocrine cells on nutrient sensing.
Single, dual and triple agonism
Reference peptides in this area engage one or more incretin receptors. Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GLP-1R/GIPR co-agonist; and retatrutide adds glucagon-receptor activity as a triple agonist. Comparative receptor engagement is precisely why these are of interest as research tools.
Research directions
Literature explores receptor pharmacology, structural biology of agonist binding, and comparative signaling between mono-, dual- and triple-agonist peptides. These are basic and pre-clinical research areas; this page describes no clinical use.
Research use only. All products and content are intended strictly for in-vitro laboratory research and analytical use. Not for human or veterinary use, not for consumption, and not for any diagnostic or therapeutic purpose.